Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP Inhibitor”

321 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 321 results

Early research (Phase 1)Ended earlyNCT06130254
What this trial is testing

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Who this might be right for
Advanced Solid TumorNon-small Cell Lung Cancers
M.D. Anderson Cancer Center 1
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Testing effectiveness (Phase 2)Study completedNCT02116777
What this trial is testing

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Who this might be right for
Adult Solid NeoplasmChildhood Solid NeoplasmRecurrent Childhood Central Nervous System Neoplasm+3 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Looking for participantsNCT05983237
What this trial is testing

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Who this might be right for
Melanoma
Jun Guo 50
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Early research (Phase 1)Study completedNCT00994071
What this trial is testing

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Who this might be right for
MedulloblastomaPontine GliomaEpendymoma+2 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Study completedNCT01078662
What this trial is testing

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Who this might be right for
OvarianBreastProstate+2 more
AstraZeneca 298
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Testing effectiveness (Phase 2)Study completedNCT03427814
What this trial is testing

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Who this might be right for
Advanced or Inoperable Gastric Cancer
BeiGene 136
Testing effectiveness (Phase 2)Study completedNCT04669002
What this trial is testing

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Ellipses Pharma 34
Early research (Phase 1)Study completedNCT03954366
What this trial is testing

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Who this might be right for
Neoplasms
pharmaand GmbH 36
Testing effectiveness (Phase 2)Study completedNCT04740190
What this trial is testing

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Who this might be right for
Recurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) Inhibitor+2 more
The University of Hong Kong 33
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Testing effectiveness (Phase 2)WithdrawnNCT01661868
What this trial is testing

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Not applicableLooking for participantsNCT06200558
What this trial is testing

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Who this might be right for
Prostate Cancer
Hospital of Macerata 534
Testing effectiveness (Phase 2)Study completedNCT02878785
What this trial is testing

Decitabine and Talazoparib in Untreated AML and R/R AML

Who this might be right for
Acute Myeloid Leukemia
University of Maryland, Baltimore 25
Testing effectiveness (Phase 2)Study completedNCT03025035
What this trial is testing

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Who this might be right for
Breast Cancer
Yuan Yuan 14
Testing effectiveness (Phase 2)WithdrawnNCT06365970
What this trial is testing

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Who this might be right for
MMR-D/MSI-H Colorectal Cancers
Ibrahim Halil Sahin
Not applicableStudy completedNCT06660147
What this trial is testing

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 243
Next Page